Abstract
Calcium channel blockers and HMG-CoA reductase inhibitors are widely used for the management of hypertension and dyslipidemia, respectively. The use of these agents in the prevention and treatment of cardiovascular disease remains largely based on their actions in lowering blood pressure and lipids. Recent clinical trials, however, indicate that certain members of these two drug classes may slow progression of disease to an extent that cannot be solely attributed to risk factor reduction. The proposed mechanisms for such pleiotropic actions include enhancement of endothelial-dependent nitric oxide bioavailability, anti-inflammatory activity, and inhibition of oxidative stress. To understand the basis for such effects, along with potential synergies, we will review the basic and clinical evidence that indicate a broader opportunity for treatment and protection of cardiovascular events by atheroprotection with these agents beyond risk factor management.
Citations
Nov 1, 2011·Current Atherosclerosis Reports·Roderick Deano, Matthew Sorrentino
Nov 10, 2009·Archives of Pharmacal Research·Soon-Pyo HongJun-Shik Choi
Nov 26, 2009·Patient Preference and Adherence·Farhan AslamJoanne Foody
May 30, 2009·Vascular Health and Risk Management·Madhuri Devabhaktuni, Sripal Bangalore
Nov 1, 2012·Indian Journal of Pharmacology·Chong-Ki LeeDong-Hyun Choi
Aug 11, 2010·Behavioural Brain Research·Harikesh KaloniaAnil Kumar
Jan 25, 2008·Pharmacology & Therapeutics·M John Chapman, Andrei C Sposito
Dec 31, 2010·The Journal of Pharmacy and Pharmacology·Soon-Pyo HongDong-Hyun Choi
Nov 13, 2012·Expert Opinion on Pharmacotherapy·Antonia Delgado-Montero, Jose L Zamorano
Jan 7, 2015·Pharmacological Reports : PR·Chong-Ki LeeDong-Hyun Choi
Dec 6, 2008·American Journal of Hypertension·Jay N CohnWilliam Sun
Jun 29, 2011·Pharmacology·Si-Hyung YangDong-Hyun Choi
Jun 19, 2013·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Chong-Ki LeeJoon Seok Bang
Oct 18, 2007·Biopharmaceutics & Drug Disposition·Dong-Hyun ChoiHyo-Kyung Han
Jan 30, 2010·Drugs·Monique P Curran
Feb 24, 2012·Pharmacological Reports : PR·Dong-Hyun ChoiJun-Shik Choi
Dec 20, 2019·Pharmaceutical Development and Technology·Amit PorwalKamla Pathak
Feb 29, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Kate McKeage, M Asif A Siddiqui